The 7 Most Common Peptide Misconceptions (And What the Research Actually Says)

The peptide conversation has gotten louder over the past few years. It has not necessarily gotten more accurate. Misconceptions about peptide therapy circulate freely — in social media, in podcast ads, in conversations between friends, sometimes even in clinic marketing materials. Some are harmless. Some lead patients to the wrong treatments. Some keep patients away from treatments that would help them.

This article addresses seven of the most common misconceptions we encounter in our consultations and what the clinical evidence actually says about each. The goal is not to defend peptide therapy. It is to be accurate about what peptides are and what they are not. For the foundational primer that underlies this whole discussion, see our Why Peptides page.

Misconception 1: “Peptides are basically steroids”

This is the most common and one of the most consequential misconceptions, because it leads patients to dismiss a legitimate category of medicine based on false equivalence.

Peptides are not steroids. They share neither the chemical structure, nor the mechanism of action, nor the side effect profile. Anabolic steroids are synthetic derivatives of testosterone. They bind to androgen receptors throughout the body, producing supraphysiologic effects with well-documented consequences — cardiovascular strain, hormonal axis suppression, liver stress, mood changes, and the rest of the profile that has earned steroids their reputation.

Therapeutic peptides operate on entirely different pathways. A growth hormone-supporting peptide like sermorelin does not contain hormone — it signals the pituitary to release endogenous growth hormone within physiologic limits. A regenerative peptide like BPC-157 acts on local tissue repair, not on the androgen system. A metabolic peptide like semaglutide affects glucose signaling, not muscle protein synthesis driven by androgen receptors.

The categories share almost nothing except that they are both medicines administered by injection. Equating them is roughly equivalent to grouping insulin and antibiotics together because both involve syringes.

Misconception 2: “All peptides are the same thing”

The word “peptide” gets used as if it refers to a single substance. It does not. Peptides are a category of molecules — the same way “antibiotics” and “blood pressure medications” are categories — and within the category, there are dozens of specific peptides with very different mechanisms and uses.

Semaglutide regulates blood sugar and appetite. BPC-157 supports tissue repair. Sermorelin signals growth hormone release. Thymosin alpha-1 modulates immune function. PT-141 acts on central nervous system pathways involved in sexual desire. These are all peptides. None of them is interchangeable with another. They target different receptors, work through different pathways, and serve different clinical purposes. Our peptide library covers more than 100 individual compounds, each with its own mechanism and clinical use.

When someone asks “do peptides work?”, the only honest answer is “which peptide, for what?” The category contains medicines with decades of FDA approval, medicines with strong preclinical data and accumulating clinical use, and medicines that are still genuinely investigational. They cannot all be evaluated together.

Misconception 3: “Peptides are unregulated”

Peptides as a category are regulated, though the regulatory landscape is more complex than for most pharmaceutical categories.

FDA-approved peptides — semaglutide, tirzepatide, PT-141, and others — go through the standard FDA approval process for specific indications. They are manufactured under pharmaceutical quality controls and dispensed by licensed pharmacies. This is the most tightly regulated portion of the category.

Compounded peptides are prepared by licensed compounding pharmacies under specific federal regulations (sections 503A and 503B of the Food, Drug, and Cosmetic Act). State boards of pharmacy oversee compounding operations. The FDA periodically issues guidance and enforcement actions on specific compounded peptides — the situation around compounded semaglutide and tirzepatide during shortage periods is an example of active FDA involvement. Compounded peptides are not unregulated, but the regulation is different from pharmaceutical manufacturing. Our clinical standards page describes our sourcing approach in detail.

What is unregulated, and what gives this misconception its grain of truth, is the gray market in research peptides — chemicals sold by chemical supply companies labeled “for research use only, not for human consumption.” These are not regulated for human use because they are not legally for human use. Patients who buy research peptides online and self-administer are operating outside the regulatory framework entirely.

The accurate framing: legal peptide therapy in the United States is regulated. The illegal market that exists alongside it is not.

Misconception 4: “Peptides are only for athletes and bodybuilders”

This misconception traces back to peptides’ visibility in performance enhancement contexts in the 2000s and 2010s. The actual clinical use of peptides has expanded dramatically and now reaches patient populations that have nothing to do with athletic performance.

GLP-1 medications are the largest peptide use case in the United States today, prescribed to patients with type 2 diabetes and chronic weight management needs through services like medical weight loss. Most are not athletes. Many have never set foot in a gym.

Regenerative peptides are used in clinical practice for post-surgical recovery, chronic injuries, and tissue repair in patients across the age spectrum. The largest user group is not athletes — it is older adults recovering from soft-tissue injuries and surgeries. Our recovery and regenerative service sees patients across this entire range.

Immune-modulating peptides like thymosin alpha-1 are used internationally for immune support in patients with chronic illness, post-viral syndromes, and immune dysregulation. Our immunity and inflammation service sees this patient population regularly.

Sleep and cognitive peptides target patients with sleep architecture issues, cognitive complaints, and stress-related neurological symptoms.

The athletic and performance use case is real, but it is a small portion of how peptides are actually used in clinical practice. The “bodybuilding drug” framing is decades out of date.

Misconception 5: “If peptides really worked, they would be FDA-approved and your insurance would cover them”

This sounds reasonable on the surface and falls apart under examination.

FDA approval is expensive. Bringing a single drug through the full FDA approval process typically costs hundreds of millions to over a billion dollars and takes a decade or more. The economics of drug development are structured around patent protection — pharmaceutical companies invest in approval only when they can recover their costs through patent-protected sales.

Most peptides used in clinical practice — BPC-157, TB-500, sermorelin, ipamorelin, thymosin alpha-1 — are either not patentable in the form they are used, or the patent windows have expired, or the indications are too narrow to justify the investment. There is no pharmaceutical company financial incentive to pursue FDA approval for these molecules.

This does not mean the molecules do not work. It means the economic structure of drug development does not align with formal approval. Several of these peptides have substantial preclinical evidence, decades of international clinical use, and accumulating practitioner experience — they simply have not been through the specific FDA approval process for specific U.S. indications.

Insurance coverage follows FDA approval and clinical guidelines, not effectiveness. Many effective medical interventions are not covered by insurance. Coverage is a function of policy and economics, not a verdict on whether something works.

The honest framing: FDA approval is a useful signal of evidence quality, but its absence is not proof that a medicine does not work. Patients should weight the evidence, not the regulatory pathway.

Misconception 6: “Peptides have to be taken forever”

This is partially true for some peptides and not true for most.

GLP-1 medications behave somewhat like blood pressure medications or thyroid hormones — when you stop them, the underlying metabolic conditions they were treating often return. Patients who lose weight on semaglutide or tirzepatide and stop the medication frequently regain a substantial portion of the weight unless they have made durable changes to the metabolic inputs (diet, exercise, sleep). Long-term use is appropriate in many of these cases, similar to how patients with hypertension take antihypertensives long-term.

Most other peptides used in clinical practice are not designed for indefinite use. Regenerative peptides like BPC-157 and TB-500 are typically prescribed in four-to-eight-week cycles tied to a specific injury — once the recovery goal is achieved, the cycle ends. Growth hormone-supporting peptides like sermorelin are typically run for three to six months at a time with rest periods between cycles, to maintain receptor sensitivity. Many longevity peptides are used intermittently or seasonally rather than continuously.

The accurate framing: cycle structure depends on the peptide and the clinical purpose. Indefinite continuous protocols are sometimes appropriate, sometimes not. A clinic that prescribes everything as ongoing therapy without clear stopping criteria is not designing protocols carefully.

Misconception 7: “Peptides will do the work for me”

This is the misconception that produces the most disappointment in patients.

Peptides are powerful signaling molecules. They are not, in most cases, substitutes for the foundational pieces of health: consistent sleep, regular training, reasonable nutrition, stress management, basic medical care for existing conditions. They are tools that amplify the work, not replacements for it.

A patient who takes a growth hormone-supporting peptide while sleeping five hours a night and not training will see modest results at best. A patient who takes a metabolic peptide while continuing the eating patterns that contributed to their starting condition will likely regain weight when the medication stops. A patient who takes a recovery peptide while continuing to overtrain the injured tissue will heal slowly if at all.

The patients who get the most out of peptide therapy are the ones who treat it as a multiplier on the work they are already doing — or are willing to start doing. The peptide does not bypass the underlying biology of how the body recovers, adapts, and improves. It supports those processes, sometimes substantially, when the inputs are present.

What honest peptide medicine looks like

Underneath all seven misconceptions is the same pattern: oversimplification in either direction. The category gets dismissed as fringe pseudoscience by people who would benefit from specific peptides. The category gets oversold as a magic solution by clinics that profit from prescribing it. Both errors are common, and both make it harder for patients to think clearly about their actual options.

Honest peptide medicine acknowledges that some peptides have decades of robust evidence and some are genuinely investigational. It distinguishes between the peptide categories that need indefinite use and the ones that should be cycled. It treats peptides as tools that fit specific clinical problems, not as a universal solution. It works alongside hormone optimization, lifestyle medicine, and conventional care rather than competing with them. And it tells patients honestly when peptides are not the right answer for their situation.

About The Tide

The Tide is a peptide-focused medical clinic in Houston, Texas. Our peptide therapy service is built around evidence-grading transparency, individualized protocols, and clinical structure — consultation, baseline labs, protocol design, and ongoing monitoring at 30, 60, and 90 days. For deeper reading on specific peptides with honest evidence accounting, see the full peptide library. To learn how protocols are designed in practice, see our programs and clinical standards.